Related Experiment Video

Updated: Jun 17, 2026

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

[Advances of study on PPARgamma/PPARgamma ligand in hematologic malignancies]

Hai-Wen Huang1, De-Pei Wu

  • 1Department of Hematology, The First Hospital, Suzhou University, Jiangsu Institute of Hematology, Suzhou 215006, Jiangsu Province, China.

Zhongguo Shi Yan Xue Ye Xue Za Zhi
|December 25, 2009
PubMed

Insights

Peroxisome proliferators activated receptorgamma (PPARgamma) shows therapeutic potential in treating hematologic malignancies. Further research into PPARgamma ligands may offer new cancer treatment strategies.

Area of Science:

  • Molecular biology
  • Gene expression
  • Cellular signaling

Context:

  • Peroxisome proliferators activated receptorgamma (PPARgamma) research is advancing.
  • PPARgamma's role in cancer is increasingly recognized.
  • Hematologic malignancies present a significant clinical challenge.

Purpose:

  • To review the current understanding of PPARgamma.
  • To explore PPARgamma's function and distribution in tissues.
  • To examine the relationship between PPARgamma ligands and hematologic malignancies.

Summary:

  • PPARgamma, a key regulator, is being investigated for its therapeutic effects in cancer.
  • This review details PPARgamma's tissue distribution and molecular functions.
  • The study links PPARgamma ligands to various blood cancers, including leukemia, lymphoma, and myeloma.

Impact:

  • Highlights PPARgamma as a potential target for novel oncotherapies.
  • Provides insights into the mechanisms of PPARgamma in hematologic cancers.
  • Informs future research directions for cancer treatment development.

More Related Videos

A Human Peripheral Blood Mononuclear Cell (PBMC) Engrafted Humanized Xenograft Model for Translational Immuno-oncology (I-O) Research08:17

A Human Peripheral Blood Mononuclear Cell (PBMC) Engrafted Humanized Xenograft Model for Translational Immuno-oncology (I-O) Research

Published on: August 15, 2019

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
Role of Hematopoietic Growth Factors01:28

Role of Hematopoietic Growth Factors

Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...